Whitehall Labs
This article was originally published in The Tan Sheet
Executive Summary
Anbesol manufacturer notifies FDA in Dec. 9 letter of the present status of three studies generating data in support of benzocaine as an OTC toothache reliever. Whitehall noted that one study has been abandoned, while a second is complete with a study report pending, and a third is ongoing. The ongoing study, enrolling 60 subjects out of a proposed 100, is expected to be finished by month's end. Responding to a September 1991 Federal Register notice declaring that insufficient data existed to classify benzocaine in Category I, Whitehall "projects submission of outstanding supportive clinical data by Feb. 28"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning